Theratechnologies Inc. is a biopharmaceutical company that develops and commercializes therapies to meet unmet medical needs in the US, Canada, and Europe. Its portfolio includes EGRIFTA, EGRIFTA SV, and Trogarzo for the treatment of HIV-associated lipodystrophy and multidrug-resistant HIV-1 infected patients. The company also has pipeline products such as F8 Formulation, TH1902, and TH1904 for the treatment of lipodystrophy in people living with HIV, triple-negative breast cancer, and ovarian cancer, respectively.